Supportive US FDA pre-IND meeting results for AD-214
Filed with ASX · · 3 pages · English
Earlier from AdAlta
- AdAlta receives approval to commence AD-214 Phase I trial
- Business update and COVID-19 response
- Board changes and R&D Tax Incentive advance received
- Investor Briefing - Strategic Plan
- AD-214 effective in gold standard pre-clinical animal model
Later from AdAlta
- First participants treated in AD-214 Phase I trial
- Investor presentation including future milestones
- Placement and Rights Offer
- Non-renounceable Rights Issue Offer
- GE Healthcare collaboration progresses
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta